Clinicaltrials.gov identifier:
NCT04794322 (https://clinicaltrials.gov/show/NCT04794322)
Prevention
Study Contact Information:
Natalie Waldron by phone: 978-394-2030 or by email
Jackie Dahlgren by email
The purpose of this study is to develop a test for early detection of ovarian cancer. Two patient populations are included in this study: women scheduled for surgery or testing for suspected but undiagnosed ovarian/fallopian tube cancer, and women with a BRCA1 or BRCA2 mutation who are scheduled for a risk-reducing salpingo-oophorectomy.
The study will examine DNA from a washing of the uterus (womb) and proteins found in the blood to see how much the study participants with ovarian cancer can be separated from the participants with a benign ovarian disease.
It is hoped that if the tests work for participants with symptoms of the disease that these tests will also work when testing women who have no symptoms, and thus improve rates of early detection of ovarian cancer.
Study participants will be recruited from two separate groups:
Both Study Group 1 and Study Group 2 will have the following diagnostic tests performed.
Participants will not receive the results of their test.
Arkansas
California
Maryland
Massachusetts
Washington
Women, age 30 years or older, are eligible if they:
Women cannot participate if they have any of the following:
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.